SA
Log In
RARE
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
32 analysts·High coverage
70
Score
27 Buy (84%)4 Hold (13%)1 Sell (3%)
Rating Breakdown
Strong Buy
00%
Buy
2784%
Hold
413%
Sell
13%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$34.00
+30.6%
Consensus
$51.00
+95.9%
Bull
$67.00
+157.3%
12-Month Target Range32 analysts
$34.00$51.00$67.00
Current $26.04Consensus
Current Price
$26.04
Upside to Consensus
$24.96

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+33.28%
EPS—
FY2028
Rev+28.40%
EPS—
FY2029
Rev+38.57%
EPS+394.05%

Earnings Surprises

Recent Analyst Actions

Apr 29, 2026Barclays
Ultragenyx price target lowered to $43 from $44 at Barclays
Target:$43.00
+75.3%from $24.53
Apr 16, 2026Morgan Stanley
Ultragenyx price target raised to $67 from $50 at Morgan Stanley
Target:$67.00
+167.8%from $25.02
Mar 12, 2026Leerink Partners
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win"
Target:$60.00
+180.9%from $21.36
Feb 18, 2026Evercore ISI
Ultragenyx price target lowered to $34 from $37 at Evercore ISI
Target:$34.00
+68.8%from $20.14
Feb 17, 2026Evercore ISI
Ultragenyx price target lowered to $37 from $39 at Evercore ISI
Target:$37.00
+80.3%from $20.52
Feb 17, 2026H.C. Wainwright
Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright
Target:$50.00
+143.7%from $20.52
Feb 13, 2026Goldman Sachs
Ultragenyx price target lowered to $61 from $71 at Goldman Sachs
Target:$61.00
+186.1%from $21.32
Feb 13, 2026Robert W. Baird
Ultragenyx price target lowered to $40 from $47 at Baird
Target:$40.00
+88.1%from $21.27
Jan 8, 2026Morgan Stanley
Ultragenyx price target lowered to $50 from $55 at Morgan Stanley
Target:$50.00
+106.6%from $24.20
Jan 5, 2026H.C. Wainwright
Ultragenyx price target lowered to $60 from $80 at H.C. Wainwright
Target:$60.00
+157.1%from $23.33
Jan 5, 2026Guggenheim
Ultragenyx price target lowered to $52 from $64 at Guggenheim
Target:$52.00
+120.3%from $23.60
Dec 30, 2025Wells Fargo
Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo
Target:$45.00
+128.2%from $19.72
Dec 30, 2025Jefferies
Ultragenyx price target lowered to $63 from $114 at Jefferies
Target:$63.00
+219.5%from $19.72
Dec 29, 2025Barclays
Ultragenyx price target lowered to $44 from $50 at Barclays
Target:$44.00
+123.1%from $19.72
Dec 29, 2025Robert W. Baird
Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird
Target:$47.00
+138.3%from $19.72
Dec 29, 2025Morgan Stanley
Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
Target:$55.00
+183.9%from $19.37
Nov 24, 2025Barclays
Ultragenyx price target lowered to $50 from $81 at Barclays
Target:$50.00
+48.9%from $33.59
Mar 17, 2025Piper Sandler
Ultragenyx price target lowered to $115 from $140 at Piper Sandler
Target:$115.00
+190.1%from $39.64
Mar 7, 2025Morgan Stanley
Ultragenyx assumed with an Overweight at Morgan Stanley
Target:$64.00
+65.7%from $38.62
Nov 6, 2024H.C. Wainwright
Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright
Target:$95.00
+85.5%from $51.20
Nov 6, 2024Leerink Partners
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
Target:$85.00
+66.0%from $51.20
Jun 6, 2024Goldman Sachs
Goldman Sachs Upgrades Ultragenyx Pharma (RARE) to Buy
Target:$67.00
+61.6%from $41.45
May 31, 2024Stifel Nicolaus
Ultragenyx Pharma (RARE) PT Raised to $127 at Stifel
Target:$127.00
+228.6%from $38.65
May 31, 2024Raymond James
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
Target:$135.00
+249.3%from $38.65
May 31, 2024Robert W. Baird
Ultragenyx Pharma (RARE) PT Raised to $72 at Baird
Target:$72.00
+86.3%from $38.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance